MMSE and CDR Score Changes and Potential Score Inflation in Multinational Alzheimer’s Disease Trials
Amanda Hackebeil, Gila Barbati, Sayaka Machizawa, Jessica Stenclik, Erica R. Appleman, Andrei Iacob, Jacqueline Massa · 2025
Read MMSE and CDR Score Changes and Potential Score Inflation in Multinational Alzheimer’s Disease Trials by Amanda Hackebeil, Gila Barbati, Sayaka Machizawa, Jessica Stenclik, Erica R. Appleman, Andrei Iacob, Jacqueline Massa (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11712556.txt.
Description
Amanda Hackebeil and co-authors (2025) investigate a quiet source of noise in Alzheimer's trials: patients whose test scores drift between screening and baseline. Two standard instruments gate entry, the MMSE memory test and the CDR dementia rating. A patient qualifying at screening sometimes no longer qualifies at baseline weeks later. One explanation is score inflation at screening — coaching, site pressure to enroll, or a good day — letting in patients outside the intended range.
The authors pooled electronic scale data from three global phase 3 trials in early Alzheimer's disease. They compared trials applying entry scores at screening only with trials re-checking at baseline. The hypothesis: larger score changes where baseline re-checks were skipped. If screening-only trials wobble more, sponsors should require the second measurement. Trial results are only as honest as the enrollment line, and this study audits the gate itself.
Catalog record
| CREATOR | Amanda Hackebeil, Gila Barbati, Sayaka Machizawa, Jessica Stenclik, Erica R. Appleman, Andrei Iacob, Jacqueline Massa |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 3 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |